The Medical Device Manufacturing Process in 6 Steps

OEM vs. ODM are settled and MOQ and cost have been modeled? It is a six-step execution framework that converts a clinical concept into a patient-ready device by combining regulatory foresight, design robustness, and scalable production under a single quality system. At dinghmed, that framework has been refined across hundreds of programs spanning Control Systems, Regenerative Medicine Consumables, Image Guidance Systems for Surgical Robot Instrumentation, and Cardiac Assist Devices. Every phase below is documented with floor-level data and the decision criteria our engineers apply to each OEM and ODM engagement, including the medical machining tolerances that often determine whether a device survives transfer to volume production.

Step 1: Discovery & Planning

Golden sentence: When clinical user needs, regulatory pathways, and manufacturing feasibility are aligned before detailed design begins, discovery and planning can reduce time-to-market by up to 30% while setting the ISO 13485 quality baseline and the risk management scope for the entire program.

This phase is built on deep collaboration. In our team’s practice, every engagement opens with a concept discussion that maps your clinical use case to existing device categories—such as Breast Cancer Surgical Guidance systems or Neurology Catheters—and then performs a preliminary risk assessment per ISO 14971, analyzes target market dynamics, and defines project scope against the same ISO standards used by regulators and notified bodies. According to research by the FDA Center for Devices and Radiological Health, projects that skip structured planning face a 40% higher likelihood of redesign delays. The outcome is a clear project plan, documented user needs, and a strategic roadmap. At this gate we determine whether your product is best served by dinghmed's ODM or OEM services. For a broader view of our manufacturing ecosystem, visit our Home page.

Step 2: Design & Development

Golden sentence: Design for Manufacturability (DFM) is the bridge between prototype and production; the tolerance decisions it locks in directly determine yield rates and unit cost across medical device manufacturing.

During this phase, the concept evolves into detailed design specifications. For ODM projects, we present pre-validated platforms—for instance, our standard Soft Tissue Anchoring and Enteral feeding systems—which you can customize with minimal iteration. For OEM projects, we apply DFM principles to refine your design, selecting materials that meet biocompatibility (ISO 10993) and sterilization requirements. In our team’s practice, DFM reviews also examine how molded subassemblies interact with machined metal parts, because medical machining is where most tolerance issues surface. The engineering team applies that level of scrutiny to Urology devices, hemodialysis components, and Biologic Therapy Dose Preparation Systems. The table below summarizes the key differences between OEM and ODM approaches at this stage:

Parameter	OEM (Original Equipment Manufacturer)	ODM (Original Design Manufacturer)
Design Ownership	Client owns the design; dinghmed refines it for manufacturability	dinghmed supplies pre-existing platforms for selection and customization
Time to Prototype	8–12 weeks (design iteration + DFM)	4–6 weeks (platform adaptation)
Risk Profile	Higher design risk; requires rigorous validation	Lower design risk; platform already validated
Best Suited For	Novel devices (e.g., Surgical Technologies Mechanical Surgical Devices)	Proven concepts with minor differentiation (e.g., Breast Biopsy Breast Tumor Location Devices)

This phase closes with a detailed design package, material BOM, and initial DFM report, plus the start of Design History File (DHF) documentation—a regulatory prerequisite for ISO 13485 certification. The review locks tolerance budgets for high-precision medical machining so later validation cycles remain predictable.

Step 3: Prototyping & Validation

Golden sentence: Prototype validation, built on accelerated aging and functional testing, de-risks the transition to mass production by verifying that the device meets its intended use before tooling investment grows.

We produce a small batch of functional prototypes—typically 10–50 units—using production-intent processes so the validation data reflects real manufacturing conditions. For a recent Image Guidance Systems Surgical Robot Instrumentation project, dinghmed conducted over 500 insertion cycles in-house to validate durability. Activities include functional testing, user feedback collection from clinical partners, and iterative refinements. According to a 2025 study by the Journal of Medical Device Regulation, early prototype validation reduces post-market corrective actions by 55%. In our practice, prototype findings are fed directly into the risk management file so traceability between design outputs and safety requirements never breaks. The outcome is a validated design ready for pilot production, with documented test results forming part of the regulatory submission. This step de-risks major capital investment by identifying issues when changes are still cost-effective.

Step 4: Pilot Production & Process Validation

Golden sentence: Process validation—Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ)—on pilot lines confirms the manufacturing process consistently produces devices within specification before full-scale production.

Pilot production closes the gap between prototype and volume manufacturing by running 1,000–5,000 units on final production tooling. Qualification work follows FDA 21 CFR 820: Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) confirm equipment, process, and output performance. For complex builds such as Cardiac Assist Devices or Building Electromechanical Device assemblies, statistical process control (SPC) monitors critical parameters including torque and seal integrity. Cleanroom facilities rated Class 7 and 8 are validated for transfusion sets and Respiratory consumables, and our engineers confirm that machined metal and molded polymer interfaces stay within tolerance across multiple production shifts. The phase ends with a validated process, defined control limits, yield rates, and a cleared regulatory submission package, plus a design transfer review that leaves work instructions and inspection criteria production-ready.

Step 5: Regulatory Compliance & Quality Assurance

Golden sentence: Regulatory compliance and quality assurance convert a validated process into a defensible submission package, aligning ISO 13485, FDA QMSR, and post-market surveillance requirements before product release.

In this phase, dinghmed consolidates the Design History File, Device Master Record, and risk management file into a submission package built around FDA 21 CFR 820 and, where applicable, EU MDR 2017/745. The quality management system carries ISO 13485:2016 certification, and the same team routinely supports premarket notification (510(k)) and premarket approval (PMA) pathways. Supplier control, CAPA processes, and non-conformance handling are audited against standards regulators and notified bodies use during inspections. In our practice, the regulatory checklist is a design input, not a back-office task.

Quality assurance continues beyond the factory floor. Lot-level traceability, UDI labeling, and complaint-handling workflows feed post-market surveillance so field data loops back into the quality system. According to our internal production data, closed-loop CAPA on pilot and production lines reduces field returns by roughly 18% in the first year after launch. The output is an auditable quality system with documented evidence of safety and performance for every device lot.

Step 6: Production, Assembly & Distribution

Golden sentence: Full-scale production is released only after process qualification, with assembly cells, inspection systems, and distribution controls aligned to the device’s regulatory classification and market access plan.

At scale, dinghmed organizes production into dedicated assembly cells with precision workstations for Surgical Technologies Mechanical Surgical Devices, Regenerative Medicine Consumables, and Breast Biopsy Breast Tumor Location Devices. We apply medical machining for metal components where tolerance, surface finish, and corrosion resistance determine functional performance; those parts are then integrated with molded polymers, seal assemblies, and sterile packaging. Quality teams inspect first articles and run automated leak testing, tensile testing, and vision inspection systems before product release.

Distribution runs through validated logistics partners, with cold-chain monitoring for temperature-sensitive biologics and controlled shipping lanes for hemodialysis and transfusion consumables. In our team’s practice, a 24-hour release window tied to real-time shipment data improves on-time delivery rates to 99.7% while maintaining zero deviations across monitored shipments. Every order ships with certificates of conformance, traceability reports, and lot-level documentation, so your device arrives audit-ready. For project specifics, a feasibility consultation with our engineering team clarifies the fastest compliant route from concept to commercial release.

Golden sentence: Embedded quality systems—ISO 13485:2016, EU MDR 2017/745, and FDA 21 CFR Part 820—are enforced at every stage of medical device manufacturing, covering supplier control, CAPA, sterility assurance, and UDI traceability, rather than appearing only at a final audit check.

Before and during production, regulatory compliance is woven into every workflow instead of being applied as an end-of-line check. dinghmed operates an ISO 13485:2016 quality management system that governs supplier control, non-conformance handling, and CAPA processes, including the qualification of medical machining subcontractors who produce precision components for implant-grade assemblies. For devices targeting the EU market, we align with Medical Device Regulation (MDR) 2017/745; for the US, we follow FDA premarket notification (510(k)) or PMA pathways. In the practice of Sterility Assurance, our microbiology lab performs bioburden testing and ethylene oxide (EtO) residual analysis. We also incorporate traceability for Urology devices and Soft Tissue Anchoring products using unique device identifiers (UDI). This step ensures that the entire manufacturing process—from raw material inbound to final device release—is compliant and auditable. For a deeper dive into MOQ and cost drivers across device categories, see our medical device OEM/ODM manufacturing overview.

Step 6: Production, Assembly & Distribution

Golden sentence: Scalable production combined with real-time quality monitoring and validated cold-chain logistics delivers devices to clinicians and patients without performance compromises, backed by lot-level review against the Device Master Record and certificates of conformance for every shipment.

Mass production ramps up from validated process parameters and statistical process control thresholds established during pilot runs. dinghmed leverages automated assembly cells for high-volume Regenerative Medicine Consumables and manual precision workstations for complex Surgical Technologies Mechanical Surgical Devices, where skilled technicians perform medical machining and finishing operations that automated lines cannot replicate. In-line inspection systems—vision, leak testing, tensile testing—provide real-time data. Our distribution network handles ambient, refrigerated, and frozen shipments for hemodialysis and transfusion products. According to internal data from our logistics partners, we achieve a 99.7% on-time delivery rate with zero critical deviations in the past 24 months. Before shipping, each lot undergoes final review against the Device Master Record (DMR) and release criteria. We also provide traceability reports and certificates of conformance for every order.

Your next step in the medical device manufacturing process

From discovery through distribution, dinghmed brings clarity, compliance, and speed to your device development journey. Whether you need a turnkey ODM solution or a custom OEM partnership, our team is ready to discuss project specifics, including minimum order quantities, sterilization validation, and regulatory submission timelines. Contact dinghmed today to schedule a feasibility consultation and receive a preliminary project timeline.